. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Transplant Cell Ther. 2021 Jan 7;27(3):262.e1–262.e11. doi: 10.1016/j.jtct.2021.01.004

Table 5.

Additional clinical outcomes by chlorhexidine gluconate usage

	High (>75%) N=25	Medium (50-75%) N=33	Low (<50%) N=45	None (0%) N=89	P-value¹
Median Days to Engraftment (IQR)	14.5 (12 - 19)	13 (12 - 16)	14 (12 - 18)	13 (12 - 19)	0.21
Febrile Neutropenia, no. (%)	16 (64%)	26 (78.8%)	31 (68.9%)	64 (71.9%)	0.64
C. difficile Infection, no. (%)	3 (12%)	3 (9.1%)	6 (13.3%)	7 (7.9%)	0.42
Rash Requiring Treatment, no. (%)	14 (56%)	13 (39.4%)	16 (35.6%)	29 (32.6%)	0.20

P-values obtained via the ordinal t-test for continuous variables or the Cochran-Armitage linear trend test for categorical variables.